Holen Sie sich die Stockscreener-App
0.9333
0.33%
0.0031
Schlusskurs vom Vortag:
$0.9302
Offen:
$0.93
24-Stunden-Volumen:
127.56K
Relative Volume:
0.46
Marktkapitalisierung:
$34.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.16M
KGV:
-1.6374
EPS:
-0.57
Netto-Cashflow:
$-8.75M
1W Leistung:
-5.73%
1M Leistung:
-10.69%
6M Leistung:
-23.50%
1J Leistung:
-9.39%
1-Tages-Spanne:
$0.90
$0.9678
1-Wochen-Bereich:
$0.90
$1.02
52-Wochen-Spanne:
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
Firmenname
Renovorx Inc
Sektor
Branche
Telefon
408-800-2649
Adresse
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.9333 | 34.09M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
Bank Watch: Can RenovoRx Inc deliver consistent EPS growth2025 Market Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
Why RenovoRx Inc. stock remains resilientBull Run & Free Daily Entry Point Trade Alerts - mfd.ru
Aug Catalysts: What drives XYZGs stock price2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
What’s the beta of RenovoRx Inc. stockJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
RenovoRx formation of RenovoCath Medical Advisory Board to support clinical and strategic initiatives - marketscreener.com
RenovoRx Forms Medical Advisory Board to Support RenovoCath - Intellectia AI
RenovoRx Establishes RenovoCath® Medical Advisory Board - Investing News Network
Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives - TradingView
RenovoRx, Inc. Establishes Medical Advisory Board to Advance RenovoCath Clinical Initiatives and Targeted Oncology Therapies - Quiver Quantitative
RenovoRx, Inc. Establishes RenovoCath Medical Advisory Board - marketscreener.com
Aug Ideas: Is RenovoRx Inc stock overvalued or fairly pricedWeekly Investment Recap & Safe Swing Trade Setup Alerts - baoquankhu1.vn
RenovoRx, Inc. Announces Change of Principal Accounting Officer - marketscreener.com
RenovoRx Appoints Veteran Executive Mark Voll as CFO - TipRanks
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer - Investing News Network
Renovorx, Inc. Appoints Mark Voll as Chief Financial Officer, Effective from February 1, 2026 - marketscreener.com
RenovoRx announces new clinical data on TAMP therapy platform - TipRanks
RenovoRx to Present New Clinical Data on Optimizing Drug Delivery in Solid Tumors at 2026 Society of Interventional Oncology Annual Meeting - Quiver Quantitative
How real-time pressure readings could sharpen chemo targeting - Stock Titan
Exit Recap: Is SunCar Technology Group Inc Equity Warrant forming a breakout patternJuly 2025 Market Mood & Community Trade Idea Sharing Platform - baoquankhu1.vn
RenovoRx (NASDAQ:RNXT) Upgraded at Jones Trading - Defense World
Pharma News: How does RenovoRx Inc perform in inflationary periods2025 Volume Leaders & Weekly Momentum Stock Picks - baoquankhu1.vn
Jones Trading initiates coverage on RenovoRx stock with Buy rating By Investing.com - Investing.com South Africa
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - The Globe and Mail
Jones Trading initiates coverage on RenovoRx stock with Buy rating - Investing.com
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting - BioSpace
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 S - The National Law Review
RenovoRx, Inc. (NASDAQ:RNXT) Is Expected To Breakeven In The Near Future - simplywall.st
Agah Ramtin, chief medical officer at RenovoRx, buys $9975 in shares By Investing.com - Investing.com Nigeria
Agah Ramtin, chief medical officer at RenovoRx, buys $9975 in shares - Investing.com India
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center - Investing News Network
RenovoRx Reports Growing Adoption of RenovoCath Device by U.S. Cancer Centers, Enhancing Targeted Oncology Treatment - Quiver Quantitative
RenovoRx, Inc. Expands RenovoCath®? Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center - marketscreener.com
Chemo-delivery device now used at nine U.S. cancer centers - Stock Titan
Loss-Making RenovoRx, Inc. (NASDAQ:RNXT) Expected To Breakeven In The Medium-Term - Yahoo Finance
Dividend Watch: Will RenovoRx Inc outperform tech stocks2025 Major Catalysts & High Accuracy Investment Signals - baoquankhu1.vn
Jobs Data: Is RenovoRx Inc stock a value trapTrade Volume Summary & Real-Time Volume Triggers - baoquankhu1.vn
Gap Down: Will RenovoRx Inc benefit from rate cuts2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
Bear Alert: What is RenovoRx Incs book value per share2025 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Pullback Watch: Will RenovoRx Inc outperform its industry peersJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 - Investing News Network
RenovoRx CEO to Provide Update on Targeted Oncology Therapies at AlphaNorth Capital Event - Quiver Quantitative
Market Fear: Can RenovoRx Inc expand its profit marginsWeekly Market Outlook & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Setups: Should value investors consider RenovoRx IncJuly 2025 Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates - MSN
How RenovoRx Inc. stock reacts to inflationary pressuresEarnings Miss & Reliable Intraday Trade Plans - ulpravda.ru
Will RenovoRx Inc. stock deliver better than expected guidanceJuly 2025 Setups & Long-Term Capital Growth Strategies - ulpravda.ru
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - The Manila Times
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - Sahm
Will RenovoRx Inc. stock reach all time highs in 20252025 Market Outlook & Low Risk High Win Rate Picks - Улправда
Finanzdaten der Renovorx Inc-Aktie (RNXT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Renovorx Inc-Aktie (RNXT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Agah Ramtin | Chief Medical Officer |
Dec 31 '25 |
Buy |
0.86 |
9,795 |
8,424 |
788,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 30 '25 |
Buy |
0.83 |
205 |
169 |
778,665 |
| Bagai Shaun | Chief Executive Officer |
Dec 18 '25 |
Buy |
0.90 |
5,000 |
4,506 |
340,040 |
| Bagai Shaun | Chief Executive Officer |
Dec 17 '25 |
Buy |
0.85 |
5,000 |
4,262 |
335,040 |
| Agah Ramtin | Chief Medical Officer |
Dec 16 '25 |
Buy |
0.85 |
12,000 |
10,200 |
778,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 05 '25 |
Buy |
0.96 |
10,000 |
9,600 |
766,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 24 '25 |
Buy |
0.80 |
12,000 |
9,600 |
756,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 21 '25 |
Buy |
0.80 |
10,000 |
8,000 |
744,460 |
| Bagai Shaun | Chief Executive Officer |
Aug 22 '25 |
Buy |
0.95 |
5,000 |
4,748 |
325,040 |
| Bagai Shaun | Chief Executive Officer |
Aug 25 '25 |
Buy |
0.91 |
5,000 |
4,549 |
330,040 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):